{ "items": [ "\n\n
\n \n\n \n \n \n \n COMRU\n \n \n \n \n MOCRU\n \n \n \n \n MORU Bangkok\n \n \n \n \n SMRU\n \n \n\n \n\n\n
\n \n\n \n23 October 2020
\n \n \n \nOxford is world-famous for research excellence and home to some of the most talented people from across the globe. To showcase our global research, the University launched a Global Research Map, highlighting areas of research we are conducting overseas.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n \n \n Public Engagement\n \n \n \n \n Video\n \n \n\n \n\n\n
\n \n\n \n14 October 2020
\n \n \n \nThe University of Oxford, MORU, the University of Cape Town, the Thai Ministry of Public Health, and UNICEF Thailand worked together to promote lifelong health and well-being, and prevent violence against children. Led by Amalee McCoy from MORU Department of Bioethics & Engagement, this project involved the cultural adaptation and testing of an evidence-based parenting intervention for low-income families with children aged 2-9 living in Udon Thani, Thailand.
\n \n\n \n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n MOCRU\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n14 October 2020
\n \n \n \nMORU\u2019s Mo Yin and MOCRU\u2019s Myo Maung Maung Swe were awarded a prize by the NDM\u2019s Graduate Studies Committee. Very competitive awards, the prizes are given annually to current or recently graduated students of NDM supervisors on the basis of their publication record, the impact and novelty of their research, references, and research within their department.
\n \n\n \n \n\n \n\n \n \n \n \n COMRU\n \n \n \n \n LOMWRU\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n21 September 2020
\n \n \n \nA series of articles that set out to explore the global distribution of infections that cause non-malarial febrile illness has been published in BMC Medicine. The series brings together the results of large-scale systematic reviews of the causes of fever in Africa, Latin America, and Southern and South-Eastern Asia, and has helped identify major knowledge gaps, geographical differences, priority areas for diagnostics research and development, and enabled the most comprehensive systematic review of literature to date.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n10 September 2020
\n \n \n \nResearch Malaria Microscopy Standards (ReMMS) applicable to malaria clinical research studies have been published in Malaria Journal. The paper describes the rationale for proposed standards to prepare, stain and examine blood films for malaria parasites.
\n \n\n \n \n\n \n\n \n \n \n \n COPCOV\n \n \n \n \n COVID-19\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n10 September 2020
\n \n \n \nAs the world waits impatiently for a COVID-19 vaccine, an exhaustive review of hydroxychloroquine and chloroquine pharmacology suggests that the doses used in COVID-19 prevention trials are safe, say University of Oxford affiliated researchers in a study published in PLoS Medicine.
\n \n\n \n \n\n \n\n \n \n \n \n COPCOV\n \n \n \n \n COVID-19\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n6 August 2020
\n \n \n \nHydroxychloroquine could still prevent COVID-19 and save tens of thousands of lives around the world, say leading scientific researchers. While it doesn\u2019t work in treatment of hospitalised patients, it could still prevent infections. However, fraudulent data, unjustified extrapolation and exaggerated safety concerns together with intense politicisation and negative publicity may stop COPCOV, the only large, global clinical trial testing hydroxychloroquine in COVID-19 prevention, from ever finding out.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n5 August 2020
\n \n \n \nBlog by Professor Christiane Dolecek. Antimicrobial resistance is a critical problem in enteric fever. Drug-resistant infections can have severe consequences, and slowing their spread requires our urgent attention. The most important intervention is to reduce the number of infections; vaccines are a critical tool, alongside surveillance and diagnosis. To achieve this control, strong partnerships between WHO, governments, NGOs, academia, private sector and communities are needed.
\n \n\n \n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n COMRU\n \n \n \n \n LOMWRU\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n14 July 2020
\n \n \n \nThe results of the University of Oxford\u2019s Recognition of Distinction exercise for Associate Professor and University Research Lecturer are in, and I am delighted to announce that the University has conferred titles on the following MORU staff:
\n \n\n \n \n\n \n\n \n \n \n \n COPCOV\n \n \n \n \n COVID-19\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n30 June 2020
\n \n \n \nThe UK regulator MHRA announced on 26 June that it would again permit recruitment to the COPCOV COVID-19 prevention clinical trial. The MHRA decision came 5 weeks after it reacted immediately to the now-discredited paper published in The Lancet suggesting harms with hydroxychloroquine, and paused recruitment of UK participants. But The Lancet paper was based on fabricated data and was swiftly retracted. After this interruption, recruitment around the globe to COPCOV can now resume.
\n \n\n \n \n\n \n\n \n \n \n \n COPCOV\n \n \n \n \n COVID-19\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n20 June 2020
\n \n \n \nPaper by NJ White et al, PLoS Medicine, in press. Using available pharmacokinetic information from healthy volunteers, the treatment of malaria, the chronic treatment of rheumatological conditions and the toxicokinetics of chloroquine in self-poisoning, the authors predict exposures and safety margins in the high dose chloroquine and hydroxychloroquine COVID-19 prevention and treatment regimens currently under evaluation. These regimens are predicted to have reasonable safety margins. Large, well conducted randomised clinical trials with appropriate monitoring are required to determine if chloroquine and hydroxychloroquine have preventive or treatment efficacy in COVID-19 and acceptable safety. Current recommendations for their use outside of clinical trials are not justified at this time.
\n \n\n \n \n\n \n\n \n \n \n \n COPCOV\n \n \n \n \n COVID-19\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n9 June 2020
\n \n \n \nOn 4 June 2020, after a week of increasing scientific concern and scrutiny, first The Lancet, then the New England Journal of Medicine, retracted studies that were based on inaccessible data. The studies have been extremely damaging to chloroquine and hydroxychloroquine COVID-19 clinical trials around the globe. MORU researchers played a key role in bringing this scandal to light, whose consequences continue to play out.
\n \n\n \n \n\n \n\n \n \n \n \n COPCOV\n \n \n \n \n COVID-19\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n5 June 2020
\n \n \n \nOn 4 June 2020, after a week of increasing scientific concern and scrutiny, first The Lancet, then a little over an hour later the New England Journal of Medicine, retracted studies that were based on inaccessible data, provided by the Surgisphere corporation. The studies have been extremely damaging to chloroquine and hydroxychloroquine COVID-19 clinical trials around the globe. Here is MORU\u2019s statement in response to these events.
\n \n\n \n \n\n \n\n \n \n \n \n COPCOV\n \n \n \n \n COVID-19\n \n \n \n \n General\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n29 May 2020
\n \n \n \nThe results of Mehra et al in The Lancet have had a considerable impact on public health practice and research, halted trials and caused considerable concern to participants and patients enrolled in randomised controlled trials (RCTs). This has led many researchers around the world to scrutinise in detail the publication and outline their concerns in this letter to Richard Horton, editor of The Lancet.
\n \n\n \n \n\n \n\n \n \n \n \n COPCOV\n \n \n \n \n COVID-19\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n26 May 2020
\n \n \n \nWe received notice from the UK's MHRA (Medicines and Healthcare Products Regulatory Agency) to pause for now new enrolment into our COPCOV study. We responded promptly to the MHRA, addressing their concerns in detail and await their decision. For now, COPCOV study enrolment is paused around the globe. The safety of our participants is our first priority, as is preventing illness in front-line healthcare workers.
\n \n\n \n \n\n \n\n \n \n \n \n COPCOV\n \n \n \n \n COVID-19\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n21 May 2020
\n \n \n \nA global study to test if either chloroquine or hydroxychloroquine can prevent COVID-19 in vital frontline healthcare workers will open to UK participants at hospital sites in Brighton and Oxford today.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n1 May 2020
\n \n \n \nThe SEBCOV study aims to produce evidence to inform public health measures such as communications, quarantine, self-isolation, social distancing, and travel restrictions for the COVID-19 pandemic. This study is run in four countries: UK, Thailand, Italy and Malaysia.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n29 April 2020
\n \n \n \nThe Epidemiology Department of MORU and National Malaria Control Programme, Cambodia (CNM) have begun to implement a study to assess the efficacy of prophylaxis with artemether-lumefantrine (PAL) against forest malaria in Siem Pang District, north-eastern Cambodia bordering Laos.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n24 April 2020
\n \n \n \nThe impact of COVID-19 is quite evident at present \u2013 entire countries and cities are under lockdown, offices and industries shut and academia at a standstill. However, many people in Bangladesh remain unaware or indifferent to the warnings and safety protocols that ought to be followed to stop COVID-19\u2019s spread. Since enforcing social distancing in a densely populated country like Bangladesh is very challenging, making people aware and maintenance of hygiene are the main means to stop the spread of COVID-19.
\n \n\n \n \n\n \n\n \n \n \n \n COMRU\n \n \n \n \n COPCOV\n \n \n \n \n COVID-19\n \n \n \n \n LOMWRU\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n23 April 2020
\n \n \n \nLess than a month after it was announced, the MORU-led COPCOV study has made quick progress and expects to begin enrolling participants by the end of April.
\n \n\n \n \n